Phio Pharmaceuticals Quick Ratio (PHIO) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Phio Pharmaceuticals Corp  (NASDAQ: PHIO)

Phio Pharmaceuticals's Quick Ratio

PHIO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 4.99 below Phio Pharmaceuticals Corp average.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Phio Pharmaceuticals in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 182 to 813.

Explain Quick Ratio?
How much Cash & cash equivalents PHIO´s has?
What are PHIO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PHIO Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 116.09 % -25.2 % 32.02 % 81.28 % -20.81 %
Y / Y Cash & cash equivalent Change 20.61 % 28.26 % 290.77 % 98.61 % 129.35 %
Quick Ratio MRQ 4.99 17.93 15.69 6.43 8.93
PHIO's Total Ranking # 813 # 182 # 88 # 370 # 325
Seq. Current Liabilities Change 174.32 % -29.1 % -19.57 % 38.14 % -5.04 %
Seq. Cash & cash equivalent Change -23.69 % -19.02 % 96.46 % -0.65 % -18.85 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 186
Healthcare Sector # 305
Overall Market # 813


Quick Ratio Statistics
High Average Low
17.93 6.45 0.17
(Mar 31 2026)   (Mar 31 2012)




Financial Statements
Phio Pharmaceuticals's Current Liabilities $ 3 Millions Visit PHIO's Balance sheet
Phio Pharmaceuticals's Cash & cash equivalent $ 13 Millions Visit PHIO's Balance sheet
Source of PHIO's Sales Visit PHIO's Sales by Geography


Cumulative Phio Pharmaceuticals's Quick Ratio

PHIO's Quick Ratio for the trailling 12 Months

PHIO Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 48.8 % 9.2 % 16.49 % -2.51 % -33.45 %
Y / Y Cash & cash equivalent TTM Growth 77.35 % 107.12 % 154.22 % 60.22 % 24.06 %
Quick Ratio TTM 9.41 11.53 10.18 7.78 7.9
Total Ranking TTM # # # # #
Seq. Current Liabilities TTM Growth 27.12 % -5.84 % 6.3 % 16.94 % -6.71 %
Seq. Cash & cash equivalent TTM Growth 3.73 % 6.73 % 38.99 % 15.26 % 21.14 %

Quick ratio ranking by company, industry and sector >> Back to PHIO Financial Strength Comparisons >> Go to Compare PHIO Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $2.61 millions, cumulative Quick Ratio decreased to 9.41 above the PHIO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Phio Pharmaceuticals. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3181.

Explain Quick Ratio?
How much Cash & cash equivalents PHIO´s has?
What are PHIO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 186
Healthcare Sector # 305
Within the Market # 813


trailing twelve months Quick Ratio Statistics
High Average Low
17.93 6.45 0.17
(Mar 31 2026)   (Mar 31 2012)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions
Coya Therapeutics Inc   12.29 $ 43.181  Millions$ 3.512  Millions
Bridgebio Oncology Therapeutics Inc   12.28 $ 634.167  Millions$ 51.634  Millions
Ocular Therapeutix Inc   12.17 $ 598.641  Millions$ 49.174  Millions
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions
Lipocine Inc   11.25 $ 23.267  Millions$ 2.068  Millions
Xenon Pharmaceuticals Inc   10.85 $ 930.686  Millions$ 85.795  Millions
Bicycle Therapeutics Plc  10.71 $ 510.052  Millions$ 47.635  Millions
Entrada Therapeutics Inc   10.44 $ 223.112  Millions$ 21.371  Millions

Date modified: 2026-09-08T20:02:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.